Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease

Masaaki Waragai, Nobuyuki Okamura, Katsutoshi Furukawa, Manabu Tashiro, Shozo Furumoto, Yoshihito Funaki, Motohisa Kato, Ren Iwata, Kazuhiko Yanai, Yukitsuka Kudo, Hiroyuki Arai

Research output: Contribution to journalArticlepeer-review

50 Citations (Scopus)

Abstract

Two techniques employed for the early diagnosis of dementia are the imaging of amyloid-β protein using positron emission tomography (PET) and voxel-based morphometry analysis of MRI (VBM-MRI). The purpose of this study was to evaluate the clinical utility of amyloid PET and VBM-MRI for the early diagnosis and tracking of the severity of Alzheimer's disease (AD). The neuritic plaque burden and gray matter losses were evaluated using [11C]BF-227-PET and VBM-MRI in 12 healthy controls, 13 subjects with mild cognitive impairment (MCI), including 6 who converted to AD and 7 who did not convert, and 15 AD patients. The AD patients and the MCI converters exhibited a neocortical retention of BF-227 and parahippocampal gray matter loss shown by VBM-MRI. The MCI converters were more clearly distinguished from the MCI non-converters in BF-227-PET than VBM-MRI. The combined sample of the MCI converters and AD patients showed a significant correlation of MMSE scores with the global gray matter loss, but not with the BF-227 retention. These findings suggest that amyloid PET using [11C]BF-227 is better suited for the prediction of conversion from MCI to AD, while VBM-MRI appears to be better suited for tracking the severity of dementia.

Original languageEnglish
Pages (from-to)100-108
Number of pages9
JournalJournal of the Neurological Sciences
Volume285
Issue number1-2
DOIs
Publication statusPublished - 2009 Oct 15

Keywords

  • Alzheimer's disease
  • Amyloid
  • BF-227
  • Early diagnosis
  • Magnetic resonance imaging
  • Positron emission tomography

Fingerprint

Dive into the research topics of 'Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease'. Together they form a unique fingerprint.

Cite this